医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Airware Labs Expands Sales into India

2015年04月21日 PM09:04
このエントリーをはてなブックマークに追加


 

SCOTTSDALE, Ariz.

Airware Labs Corporation (OTCQB: AIRW) today announced 37 Apollo Hospitals and 250 Apollo pharmacy retail outlets across India will now sell Airware Labs’ innovative AIR ALLERGY product. Apollo Pharmacy is the largest retail pharmacy chain in India. Apollo Hospitals, based in Chennai, India, encompass over 10,000 beds across the country. A number of Apollo Hospitals have been among the first in India to receive international healthcare accreditation. Apollo hospitals and pharmacies are a part of the Apollo Group.

Airware Labs’ AIR ALLERGY will be available in retail and hospital-based outlets in the Hyderabad Region, Chennai Region, Mumbai Region, Delhi Region, Kolkata Region and Bangalore Region. According to Airware Labs CEO Jeffrey Rassas, “We are very excited about the opportunity to partner with an organization that is dedicated to giving every citizen in India access to the highest quality of healthcare. Airborne pollutants remain a devastating problem across India. Many people may not realize that New Delhi is now the most polluted city in the world. With air pollution cited as the 5th largest killer in India and more than 30 percent of the population suffering from one or more allergens, our AIR ALLERGY product offers an effective, affordable choice in addressing serious health challenges.”

AIR ALLERGY is a discreet personal filter that features a 3M filtration media to stop allergens as well as a blend of proven, therapeutic premium oils to provide additional antimicrobial protection and symptomatic relief. AIR ALLERGY is part of the line of Airware Labs’ healthcare products that are marketed under the brand name of AIR and include pioneering, over-the-counter consumer products that address airborne bacteria and viruses, allergies, congestion, snoring, insomnia, nausea, headaches, and enhanced sports performance. Unlike external products such as strips, these soft, comfortable, and discreet, latex- and drug-free products fit just inside the nose, utilizing an FDA-approved medical-grade material. Nearly invisible for use anytime and anywhere, the AIR products’ microstructure enhances normal nasal airflow with every breath and is clinically proven to deliver up to 40 percent more oxygen.

The sale of Airware Labs’ AIR ALLERGY product in India marks another step forward in the successful execution of the company’s plan to rapidly grow its domestic and international market penetration through partnerships with leading retail and health locations. “With the ongoing interest in preventive healthcare, our leading-edge products represent effective, affordable choices for consumers. We are delighted by the growth in consumer awareness and adoption of our pioneering products, which we expect will fuel continued growth going forward,” commented Rassas.

Recently, Airware Labs announced a new domestic partnership with Winn Dixie and BI-LO stores across the country. Airware Labs’ products are also available in the U.S. through a number of brick and mortar retail locations including Walgreens, Albertsons, Acme, Shoppers, Shop n’ Save, ACME, and Farm Fresh along with individual distributors in the United States, Canada, and Europe. Online the products are available at a variety of retail sites including Walmart, Walgreen’s, Target, Drugstore.com, CVS, Amazon and Airware Labs.

About Airware Labs Corporation: Airware Labs Corp. (publicly traded as OTCQB: AIRW) provides patented, innovative breathing technology products that promote better health and enhanced wellbeing in addition to a new line of skin care products. The company is headquartered in Scottsdale, Arizona. Explore our extensive product line at http://www.airwarelabs.com and learn more about our company by visiting http://airwarelabscorp.com.

Forward-Looking Statement: The statements in this press release regarding any implied or perceived benefits from the release by Airware Labs Corp. of its products are forward-looking statements. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

CONTACT

Airware Labs Corporation
Media Contact:
Sharon Schultz,
301-351-0109
schultzpr@mchsi.com
or
Investor
Relations:

Jeffrey Rassás, 480-463-4246
Free:
877-876-4868
jeffrey@airwarelabs.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Clover Biopharmaceuticals Completes RMB 62.8 Million Series A Financing
  • 三叶草生物制药完成6,280万元人民币A轮融资
  • Corindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.
  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表